KDNY - Chinook Therapeutics begins dosing in phase 1 trial of CHK-336

Chinook Therapeutics (NASDAQ:KDNY) began dosing in a phase 1 trial of CHK-336 in adult healthy volunteers. The company is developing CHK-336 for treating patients with primary hyperoxaluria (PH) and secondary hyperoxaluria due to increased endogenous oxalate production. Hyperoxalurias occurs when there is excess oxalate in the urine. PH is a rare genetic disorder in which the liver does not create enough of a certain enzyme that prevents overproduction of oxalate. The extra oxalate can combine with calcium to create kidney stones which can damage the kidney. The early stage-study will evaluate the drug in up to 104 healthy people.

For further details see:

Chinook Therapeutics begins dosing in phase 1 trial of CHK-336